South Korea Mulls Revision Of Price Volume Agreement, Stoking Opposition Across Industry
This article was originally published in PharmAsia News
Executive Summary
Industry expects proposed price volume agreement revisions would cut prices for drugs that exceed year-on-year sales increases of only $4.4 million.